This Article Full Text Full Text (PDF) All Versions of this Article: 33/12/3033    most recent 01.STR.0000039405.31526.06v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shuaib, A. Articles by Noor, R. Search for Related Content PubMed PubMed Citation Articles by Shuaib, A. Articles by Noor, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Stroke Related Collections Animal models of human disease Brain Circulation and Metabolism Neuroprotectors

(Stroke. 2002;33:3033.)
© 2002 American Heart Association, Inc.

Research Reports

Effects of Nonpeptide V₁ Vasopressin Receptor Antagonist SR-49059 on Infarction Volume and Recovery of Function in a Focal Embolic Stroke Model

From the Stroke Research Laboratory, Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta, Canada.

Reprint requests to Dr A. Shuaib, 2E3.13 WMHSC, Division of Neurology, University of Alberta Hospital, Edmonton T6G 2B7, Canada. E-mail ashfaq.shuaib{at}ualberta.ca

Abstract

Background and Purpose— Cerebral edema develops very early after the onset of focal cerebral ischemia and may be a major factor in early disability after an acute ischemic stroke. There have been very limited studies on the usefulness of antiedemic agents as neuroprotective agents in the setting of focal cerebral ischemia. We tested the neuroprotective effects of a new potent nonpeptide vasopressin receptor V₁ antagonist, SR-49059, in a focal embolic stroke model in rats.

Methods— Focal ischemic injury was induced by embolizing a preformed clot into the middle cerebral artery (MCA). Infarction volume was measured at 48 hours after the MCA occlusion. Neurological deficits, ischemic brain edema, seizure activity, and mortality and hemorrhage rates were also documented.

Results— Treatment with SR-49059 (2 mg/kg), initiated immediately after MCA occlusion, significantly reduced infarction volume (P<0.05) measured at 48 hours after the arterial occlusion. In animals in which the treatment was delayed for 1 hour after MCA occlusion, infarction volume was also reduced significantly (P<0.05). Infarction volume in the rats that received the drug at 3 or 6 hours after MCA occlusion was not different from that in the vehicle-treated group. Treatment with SR-49059, when started early after the arterial occlusion, also reduced neurological deficits and ischemic brain edema. Injection of drug at a higher dose (30 mg/kg) also reduced infarction volume and improved functional recovery but was not superior to the lower dose (2 mg/kg) when the drug was administrated at 1 hour after MCA occlusion.

Conclusions— Our data show that the selective vasopressin receptor antagonist SR-49059 is a potent neuroprotective agent when used early after onset of arterial occlusion in an embolic focal ischemia model in rats. Further studies are needed in stroke models to better understand its neuroprotective properties when used alone or in combination with thrombolysis.

Key Words: arterial occlusive diseases • brain edema • ischemia • rats

This article has been cited by other articles:

				T. I. Lam, P. M. Wise, and M. E. O'Donnell Cerebral microvascular endothelial cell Na/H exchange: evidence for the presence of NHE1 and NHE2 isoforms and regulation by arginine vasopressin Am J Physiol Cell Physiol, August 1, 2009; 297(2): C278 - C289. [Abstract] [Full Text] [PDF]

				S. F. Pedersen, M. E. O'Donnell, S. E. Anderson, and P. M. Cala Physiology and pathophysiology of Na+/H+ exchange and Na+-K+-2Cl- cotransport in the heart, brain, and blood Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2006; 291(1): R1 - R25. [Abstract] [Full Text] [PDF]

				M. E. O'Donnell, V. Duong, J. Suvatne, S. Foroutan, and D. M. Johnson Arginine vasopressin stimulation of cerebral microvascular endothelial cell Na-K-Cl cotransporter activity is V1 receptor and [Ca] dependent Am J Physiol Cell Physiol, August 1, 2005; 289(2): C283 - C292. [Abstract] [Full Text] [PDF]

				R. Noor, C. X. Wang, and A. Shuaib Hyperthermia Masks the Neuroprotective Effects of Tissue Plaminogen Activator Stroke, March 1, 2005; 36(3): 665 - 669. [Abstract] [Full Text] [PDF]